WO2006012577A3 - Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments - Google Patents

Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments Download PDF

Info

Publication number
WO2006012577A3
WO2006012577A3 PCT/US2005/026192 US2005026192W WO2006012577A3 WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3 US 2005026192 W US2005026192 W US 2005026192W WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
food intake
quinazolinone derivatives
derivatives useful
glucose homeostasis
Prior art date
Application number
PCT/US2005/026192
Other languages
English (en)
Other versions
WO2006012577A2 (fr
Inventor
Joachim Rudolph
Stephen O'connor
Philip Coish
Philip Wickens
Georgiy Bondar
Chih-Yuan Chuang
Philip Ramsden
Derek Lowe
Donald Bierer
Libing Chen
Wenlang Fu
Uday Khire
Xiao-Gao Liu
Andrea Mcclure
Lei Wang
Lin Yi
William Esler
Original Assignee
Bayer Pharmaceuticals Corp
Joachim Rudolph
Stephen O'connor
Philip Coish
Philip Wickens
Georgiy Bondar
Chih-Yuan Chuang
Philip Ramsden
Derek Lowe
Donald Bierer
Libing Chen
Wenlang Fu
Uday Khire
Xiao-Gao Liu
Andrea Mcclure
Lei Wang
Lin Yi
William Esler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Joachim Rudolph, Stephen O'connor, Philip Coish, Philip Wickens, Georgiy Bondar, Chih-Yuan Chuang, Philip Ramsden, Derek Lowe, Donald Bierer, Libing Chen, Wenlang Fu, Uday Khire, Xiao-Gao Liu, Andrea Mcclure, Lei Wang, Lin Yi, William Esler filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006012577A2 publication Critical patent/WO2006012577A2/fr
Publication of WO2006012577A3 publication Critical patent/WO2006012577A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Abstract

La présente invention a trait à des dérivés de la quinazolinone, des compositions, et des procédés de traitement du diabète, de l'obésité et autres troubles associés, et de la régulation de la prise d'aliments (par exemple, stimulation et suppression).
PCT/US2005/026192 2004-07-22 2005-07-22 Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments WO2006012577A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59080404P 2004-07-22 2004-07-22
US60/590,804 2004-07-22

Publications (2)

Publication Number Publication Date
WO2006012577A2 WO2006012577A2 (fr) 2006-02-02
WO2006012577A3 true WO2006012577A3 (fr) 2006-09-28

Family

ID=35786753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026192 WO2006012577A2 (fr) 2004-07-22 2005-07-22 Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments

Country Status (1)

Country Link
WO (1) WO2006012577A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838296B1 (fr) 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoides et isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
CA2636981A1 (fr) * 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, leur fabrication et leur utilisation en tant qu'inhibiteurs des proteines kinases
ATE523500T1 (de) * 2006-09-11 2011-09-15 Organon Nv Chinazolinon- und isochinolinon-acetamid-derivate
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作***相关受体调节剂的化合物及其应用
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
AU2009262252B2 (en) * 2008-06-26 2013-05-02 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作***相关受体调节剂的化合物及其应用
FR2938538B1 (fr) * 2008-11-17 2011-08-05 Univ Nice Sophia Antipolis Procede de preparation d'acides et d'esters boroniques en presence de magnesium metallique
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
DK2421533T3 (en) 2009-04-22 2019-01-07 Resverlogix Corp Hitherto unknown anti-inflammatory agents
WO2011075699A2 (fr) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Composés pour le traitement des troubles médiés par le récepteur métabotropique 5 du glutamate, et leurs méthodes d'utilisation
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
GB201313664D0 (en) 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
WO2018184115A1 (fr) * 2017-04-06 2018-10-11 London Health Sciences Centre Research Inc. Dérivés de quinazolinone utiles pour l'imagerie
WO2019104324A1 (fr) * 2017-11-27 2019-05-31 The Scripps Research Institute Antagoniste de ghsr1a pour le traitement du syndrome de prader-willi
CN110698392A (zh) * 2019-09-09 2020-01-17 中国农业大学 一种双酰胺类化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (fr) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Derives de la piperidine
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (fr) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Derives de la piperidine
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAKER B.R. ET AL.: "An Antimalarial Alkaloid From Hydrangea. IV. Functional Derivatives of 3-Alkyl-4-Quinazolones", J. ORG. CHEM., vol. 17, 1952, pages 35 - 51 *

Also Published As

Publication number Publication date
WO2006012577A2 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006012577A3 (fr) Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2007016538A3 (fr) Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
WO2006044775A3 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2006020959A3 (fr) Heterocycles benzo-condenses substitues
WO2007041130A3 (fr) Deazapurines convenant comme inhibiteurs des janus kinases
WO2005119627A3 (fr) Dispositifs personnels de controle de la nutrition
WO2008116139A3 (fr) Composés utiles en tant qu'inhibiteurs des kinases de janus
WO2007109354A3 (fr) Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2007104053A3 (fr) Inhibiteurs de la 8-hétéroarylpurine mnk2 pour le traitement de troubles métaboliques
WO2007041365A3 (fr) Composes organiques
WO2008076392A3 (fr) Composés utilisables en tant qu'inhibiteurs de protéines kinases
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2005046603A3 (fr) Composes pyridiniques
EP1633722A4 (fr) Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2006034154A3 (fr) Sels de 5-azacytidine
WO2006113919A3 (fr) Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
WO2007079214A3 (fr) Antagonistes du recepteur de la prokineticine 2
WO2009068246A3 (fr) Procédés de traitement de l'obésité et de troubles métaboliques
WO2007050793A3 (fr) Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2009042922A3 (fr) Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation
WO2005115446A3 (fr) Detection et utilisation de prolylcarboxypeptidase
WO2006034491A3 (fr) Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase